G2GBio announced on the 19th that it has signed a platform evaluation contract with Chinese pharmaceutical company The United Bio-Technology (Hengqin) Co., Ltd. (UBT) for the development of long-acting injectables.

According to the disclosure, the two companies entered into both a material transfer agreement and a platform evaluation agreement for this evaluation. The core of the deal is to assess development feasibility by applying G2GBio's long-acting injectable development platform 'InnoLAMP' to a specific candidate substance provided by UBT.

The contract was signed on October 19, 2026. The contract period runs until the earlier of the conclusion of the research or 12 months from the contract date, and may be extended upon written agreement between the two companies.

The contract amount was not disclosed at the request of the counterparty for confidentiality. G2GBio stated that the contract consists of an upfront payment and milestones, and that the upfront payment is subject to disclosure obligations as it equals or exceeds 10% of the previous fiscal year's revenue. Contract-related information, including the contract amount and development target items, as well as data to be developed, cannot be disclosed under the confidentiality clauses of the contract. The withholding period for disclosing the contract amount extends until April 16, 2031, the same date as the termination of contractual obligations under the non-disclosure agreement (NDA) signed by the two companies.

Notable contract terms include the right of both parties to terminate the contract upon mutual agreement or in the event of a material breach. However, there is no obligation to return the contract payment upon termination.

G2GBio explained that both the date of occurrence and the decision date of this contract were October 19, which is the date the two companies signed the final contract in Korean time.